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a b s t r a c t
Incorporation in a 20 ? 50 direction of a phosphorodiamidite 20-amino-LNA-T nucleotide as the mor-
pholino phosphoramidate and N,N-dimethylamino phosphorodiamidate monomers into six oligonu-
cleotides is reported. Thermal denaturation studies showed that the novel 20-amino-LNA-based
morpholino monomers exert a destabilizing effects on duplexes formed with complementary DNA and
RNA.
 2017 Elsevier Ltd. All rights reserved.
Phosphorodiamidate morpholino oligonucleotides (PMOs) (1,
Fig. 1) are used as antisense tools in gene knockdown experi-
ments.1 They act as steric blockers, do not degrade their target
RNA,2 and are enzymatically stable.3 Current investigations of
PMOs and conjugates thereof as therapeutics for amending splicing
defects ex vivo and in vivo are underway.4–14 Recently the first
PMO-drug Eteplirsen/Exondys 51 was approved by the FDA for
treatment of Duchenne muscular dystrophy.15
Methods to synthesize PMOs in a 50 ? 30 direction (reverse-
direction compared to standard oligonucleotide synthesis) utilize
either an N-trityl-50-chlorophosphorodimethylamidate16,17 or an
N-trityl-50-H-phosphonate18 morpholino building block (2 and 3,
Fig. 1). Recently, we have developed a method for synthesizing
PMOs and PMO-DNA chimeras in 30 ? 50 direction. This procedure
uses silyl-protected nucleobase morpholino building blocks and
oxidative substitution of a borane phosphonate oligonucleotide
intermediate.19
Because of the current interest in PMOs, we decided to explore
other morpholino-based monomers including the 20-amino-LNA
nucleotide (5, Fig. 1), a derivative of LNA (locked nucleic acid) (4,
Fig. 1) having a 20N-40C methylene bridge. LNA and 20-amino-LNA
are conformationally locked nucleotides20 of which the latter can
be considered a bicyclic morpholino-based ring system (5, Fig. 1).
When incorporated into oligonucleotides, the 20-amino functional-
ity faces the minor groove of nucleic acid duplexes.21 This site in
oligonucleotides therefore provides a convenient handle when N-
acylated and N-alkylated21 for appending amino acids residues,22
fluorescence probes,23–26 nucleobases27 and a piperizino group28
while preserving the LNA-type high-affinity hybridization with
complementary DNA and RNA strands. A new synthon, 30-O-ben-
zyl-20-amino-LNA-T phosphorodiamidite, was used to prepare an
alternative morpholino analogue having a 20-50 linkage (6 and 7,
Fig. 1) and the 30-hydroxyl protected through a benzyl group.
Molecular modelling studies were performed in order to assess
the structure of 30-O-benzyl-20-amino-LNA-T phosphoramidate
monomer 6 in a DNA:DNA duplex. In order to complete this study,
a 9-mer duplex consisting of DNA:RNA [50-d(CTGATATGC):50-r
(GCAUAUCAG)] was downloaded from the protein data bank
(PDB entry pdb 1HG9),29 the RNA strand was converted to DNA
and 30-O-benzyl-20-amino-LNA phosphoramidate monomer 6 was
inserted in d(CTGAXATGC) as monomer X. An AMBER⁄ force field
in Macro Model 9.1 was used to generate representative low
energy structures.
This modelling study indicated that the 30-O-benzyl-20-amino-
LNA-T is locked into a 30-endo (N-type) conformation (Fig. 2a) in
a manner similar to 20-amino-LNA-T monomer 5 inserted into
the same duplex (Fig. 2b). Moreover both monomers 5 and 6
exhibited excellent stacking interactions with the neighboring
http://dx.doi.org/10.1016/j.bmcl.2017.05.023
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nucleobases and nucleobase positioning suitable for engaging into
Watson–Crick base pairs (Fig. 2a and b). It is also evident from the
molecular modelling that the 30-O-benzyl group is protruding from
the duplex into the minor groove and covers part of the phospho-
rous backbone. Based upon this modelling study, the 30-O-benzyl
and the locked morpholino scaffold seemed not to impede Wat-
son-Crick base pairing thus giving us an incentive to begin an
experimental evaluation of novel constrained morpholino mono-
mers 6 and 7 in the context of DNA and RNA oligomers. In this
manuscript, we describe the first synthesis procedures for incorpo-
ration of these monomers into oligonucleotides and present an
evaluation of their duplex stability.
The phosphorodiamidite 9 (Scheme 1) was obtained in 87%
yield from the 30-O-benzyl derivative 8 using 2-cyanoethyl-N,N,
N0,N0-tetraisopropylphosphorodiamidite as phosphitylating
reagent and 4,5-dicyanoimidazole (DCI) as activator.
As outlined in Fig. 3, two generalized pathways were used with
synthon 9 in order to prepare oligonucleotides containing the
monomers 6 or 7. For the preparation of 6, the first step was treat-
ment with acid to remove the dimethoxytrityl group. Synthon 9
was then activated and coupled with the growing oligonucleotide
in order to generate the phosphoramidite internucleotide linkage.
Following oxidation and capping, the cycle can be repeated using
synthon 9 or the standard 20-deoxynucleoside 30-phospho-
ramidites. The synthesis of 7 required modification of this cycle.
The detritylation step had to be carried out with trimethylphos-
phite borane (TMPB) in the presence of acid. TMPB reacts with
the generated dimethoxytrityl cation and therefore prevents for-
mation of an internucleotide tritylphosphonate linkage. Following
coupling with 9, boronation and capping completed the synthesis
steps for one cycle. In order to evaluate the overall yield and the
extent of degradation, various coupling conditions were explored
and the results are shown in Fig. S3 and Table S1 (ESIy). Based upon
these results, we conclude that the optimal conditions were 0.10 M
tetrazole for each of two coupling rounds of 900 s each giving80%
total stepwise coupling yield.
For the synthesis of PMO-DNA chimeras containing monomer 7,
the borane phosphonate intermediate was converted, through
oxidative substitution,20 to the N,N-dimethylamino phosphorodi-
amidate (see Fig. S2, ESIy). This post-synthetic transformation con-
sisted of 1) detritylation, 2) removal of the cyanoethyl substituent
with MeCN:NEt3 (1:1; v/v) (thereby also oxidizing P(III) to P(V)), 3)
oxidative substitution by reaction with I2 and dimethylamine, and
4) cleavage from the solid support using sat. aqNH3. The reaction
steps 1–2 were performed on the column whereas steps 3–4 were
completed on the polystyrene-resin in glass-vials.
Using synthon 9 and the standard 20-deoxynucleoside 30-phos-
phoramidites, oligonucleotides ON2-ON5 and ON7-ON8 were syn-
thesized, characterized by LC-MS, and used to evaluate the effect of
the novel constrained morpholino monomers on duplex stability.
ON1-ON10 were hybridized to complementary DNA or RNA and
thermal denaturation experiments were conducted in a medium
salt buffer (Table 1). When ON2-ON5 were hybridized to DNA,
one incorporation of monomer 6 induced a drastic drop in Tm value
of 14.5 C for ON2 while no detectable transition above 5 C was
observed for ON3 with four incorporations of monomer 6. Replac-
ing the phosphoramidate monomer 6 with the N,N-dimethylamino
phosphorodiamidate monomer 7 induced a significant but less
pronounced decrease in stability as one incorporation reduced
the Tm value by 10.5 C for ON4. This difference is most likely
due to less electrostatic charge repulsion, since monomer 7 does
not have a negative charge. With two incorporations of monomer
7 into ON5 no transition was observed. With complementary
RNA, no transition above 5 C was observed for ON2-ON5.
The mixed-base sequences ON7 and ON8 show a similar pattern
with a significant drop in Tm of -10 C towards complementary
DNA and of -7 C towards complementary RNA for one incorpora-
tion of monomer 6, and with three incorporations the drop in Tm
value was even more pronounced. Additionally, Tm-measurements
were performed on two reference oligonucleotides containing 20-
amino-LNA-T nucleotides incorporated in the 30 ? 50 (standard
manner) with a phosphodiester backbone as monomer 5 (Fig. 1)
(ON9 and ON10). These measurements showed the expected large
increases in thermal stability in sharp contrast to the effects of the
two morpholino-based incorporation motifs introduced herein.
The decrease in thermal stability might in part be due to the
20 ? 50 incorporation pattern of monomer 6 and 7 as strong desta-
bilization has previously been reported upon incorporation of one
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Fig. 1. A) Chemical structures of phosphorodiamidate morpholino oligonucleotides
(PMO, 1) and the morpholino building blocks (2 and 3) used to synthesize PMO in a
60 ? 30 direction. B) Chemical structures of phosphordiester monomers of LNA, 4
and 20-amino LNA, 5. Structure 6 shows the 20-amino-LNA-T phosphoramidate
monomer and structure 7 the 20-amino-LNA-T dimethylamino phosphorodiamidate
monomer. B = nucleobases and T = thymin-1-yl.
Fig. 2. Snapshots from molecular dynamics simulations of a 9-mer duplex [(50-d
(CTGAXATGC):50-d(GCATATCAG)] modified at the central position (X) with a) 30-O-
benzyl-2-amino-LNA phosphoramidate monomer 6, and b) 20-amino-LNA-T mono-
mer 5. See ESIy Fig. S7 for a larger display including a snapshot of the dinucleotide
structure showing more clearly the sugar pucker of the modified monomers 5 and
6.
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Scheme 1. Synthesis of the phosphorodiamidite 9. T = Thymin-1-yl.
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or few 20 ? 50 linked 30-deoxy monomers into DNA duplexes.30
Notably, a 30-deoxy derivative of monomer 6 has been
incorporated into DNA and morpholino oligomers, but melting
temperatures were reported only for the latter which makes direct
comparison with our data (Table 1) impossible.31
In conclusion the 30-O-benzyl-20-amino-LNA-T phosphorodi-
amide 9 was successfully synthesized and incorporated in a 20 ?
50 direction into six oligonucleotides as either one or three phos-
phoramidate monomer(s) 6 (ON2, ON3, ON7, and ON8) or, through
a borane phosphonate intermediate, as one or two N,N-dimethy-
lamino phosphorodiamidate monomer(s) 7 (ON4 and ON5) giving
chimeric PMO-DNA oligomers. Thermal denaturation experiments
revealed a significant decreasing effect on duplex stability of these
monomers which may at least in part be explained by interference
of 30-O-benzyl group on the hydration of the phosphorus backbone.
A further development could be to select a removable protecting
group for the 30-hydroxy function or to use a 30-O-methyl sub-
stituent as a sterically less demanding group.
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10:0.5:89.5 v/v/v, boronation using 0.05 M BH3 in THF and the post-synthetic transformation followed by cleavage from resin using sat. aqNH3. B = Nucleobases and
T = Thymin-1-yl monomer.
Table 1
Thermal denaturation studies for synthesized oligonucleotidesa.
Sequence Tm-values in medium salt buffer
Complementary DNA Complementary RNA
50-TTT-TTT-TTT-T-30 ON1 19.5 C 13.5 C
50-TTT-TT6-TTT-T-30 ON2 5.0 C (14.5 C) <5.0 C
50-TTT-666-6TT-T-30 ON3 <5.0 C <5.0 C
50-TTT-TT7-TTT-T-3 ON4 9.0 C (10.5 C) <5.0 C
50-TTT-T77-TTT-T-30 ON5 <5.0 C <5.0 C
50-GTG-ATA-TGC-30 ON6 31 C 27.5 C
50-GTG-A6A-TGC-30 ON7 20.5 C (10 C) 20.5 C (7 C)
50-G6G-A6A-6GC-30 ON8 5.0 C (26 C) 6.0 C (21.5 C)
50-GTG-A5A-TGC-30 ON9 34.5 C (+3.5 C) 35.5 C (+8 C)
50-G5G-A5A-5GC-30 ON10 40.0 C (+9 C) 48.5 C (+21 C)
a Thermal denaturation temperatures of DNA-DNA and DNA-RNA duplexes
measured as the average of the maxima of the first derivatives of the melting curves
(A260 versus temperature) from two independent melting temperature determi-
nation with a deviation <0.5 C. Numbers in brackets are DTm values measured in
degrees Celsius as the difference in Tm-values between modified and unmodified
duplexes. The experiments were recorded in medium salt buffer (6.1 mM sodium
phosphate, 100 mM sodium chloride, 0.1 mM EDTA, pH 7.0 using 1.5 M concen-
trations of the two complementary strands (assuming identical extinction coeffi-
cients for all modified and unmodified oligonucleotides); 5 = 20-amino-LNA-T
phosphodiester monomer, 6 = 20-amino-LNA-T phosphoramidate, 7 = 20-amino-
LNA-T N,N-dimethylamino phosphorodiamidate, T = thymin-1-yl monomer, C =
cytosine-1-yl monomer, A = adenine-9-yl monomer and G = guanine-9-yl
monomer.
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